![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
The Effect of Renal Impairment on Multiple-dose Pharmacokinetics of the Fixed-dose Combination of Daclatasvir/Asunaprevir/Beclabuvir
|
|
|
Reported by Jules Levin
DDW 2015 May 16-19 Wash DC
Robert Adamczyk,1 Karen Sims,1 Michael Hesney,1 Megan Wind-Rotolo,1 Michele Stonier,1 Ruth Penn,2 Laurie Reynolds,2 Frank LaCreta,1 Malaz AbuTarif1
1Bristol-Myers Squibb Research and Development, Princeton, NJ, USA; 2ICON, Development Solutions, Hanover, MD.
![HCV1.gif](../images/063015/062915-2/HCV1.gif)
![HCV2.gif](../images/063015/062915-2/HCV2.gif)
![HCV3.gif](../images/063015/062915-2/HCV3.gif)
![HCV4.gif](../images/063015/062915-2/HCV4.gif)
![HCV5.gif](../images/063015/062915-2/HCV5.gif)
![HCV6.gif](../images/063015/062915-2/HCV6.gif)
![HCV7.gif](../images/063015/062915-2/HCV7.gif)
![HCV8.gif](../images/063015/062915-2/HCV8.gif)
![HCV9.gif](../images/063015/062915-2/HCV9.gif)
![HCV10.gif](../images/063015/062915-2/HCV10.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|